ONC reports its first-quarter 2026 results today — and the most telling signal heading in is not short positioning but the rapid accumulation of bullish analyst coverage on a stock that remains well below most price targets.
The analyst setup is decidedly constructive. Wells Fargo initiated coverage just three days ago with an Overweight rating and a $400 target. Wolfe Research launched coverage in late March at Outperform with a $340 target. Those fresh initiations follow a cluster of target raises in late February from Barclays, Truist, and Guggenheim, all maintaining positive ratings and lifting targets into the $400–425 range. Against a current price of $313.32, the consensus mean target of $409 implies roughly 37% upside — placing ONC in the 99th percentile for analyst return potential in its universe. The sole outlier is Jefferies, which downgraded to Hold and cut its target to $290 in mid-March, citing execution risk. The Street is broadly constructive; the debate is over how fast the bull case materialises.
That bull case centres on Brukinsa, BeOne's lead BTK inhibitor. Bulls model Brukinsa reaching approximately $7.1 billion in peak sales by 2034, with sonrotoclax providing a next-generation pipeline leg. The company has already crossed into profitability — estimated net income of around $750 million on revenue near $6.4 billion — and generates positive operating cash flow of roughly $1 billion. Bears push back on execution risk in a competitive oncology market, the pace of physician uptake, and geopolitical exposure given BeOne's dual US-China footprint. The company's EPS momentum rank sits in the 88th percentile on a 30-day basis, suggesting estimates have been moving in the right direction ahead of today's print.
Short sellers are largely absent from this story. Short interest is under 1% of free float and has fallen 25% over the past month. Borrow costs are negligible at 0.55% annualised, and availability is wide — meaning there is no squeeze dynamic and no meaningful hedging pressure from the lending market. Options positioning has softened relative to recent weeks: the put/call ratio of 1.24 is about 1.5 standard deviations below its 20-day average of 1.37, indicating options traders have actually trimmed defensive positioning into the event rather than adding to it. Insider activity in the window has been limited to routine selling by the General Counsel — no material signal either way.
The print is therefore less about whether BeOne is growing and more about whether Brukinsa's trajectory and margin profile justify a rerating from $313 back toward the analyst consensus that has clustered firmly above $400.
See the live data behind this article on ORTEX.
Open ONC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
